Abeona Therapeutics Inc. buy melinda
Start price
26.05.19
/
50%
€136.09
Target price
15.02.20
€180.40
Performance (%)
-44.15%
End price
15.02.20
€76.00
Summary
This prediction ended on 15.02.20 with a price of €76.00. Massive losses of -44.15% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Abeona Therapeutics Inc. | -58.310% | -58.310% | 5.488% | -91.131% |
iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
According to melinda what are the pros and cons of Abeona Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Abeona Therapeutics Inc. diskutieren
Secteur Recherche biotechnologique et médicale Agenda 28/05 Assemblée générale
Abeona Therapeutics Inc. est une société biopharmaceutique au stade clinique qui développe de nouvelles thérapies géniques pour les maladies génétiques rares potentiellement mortelles. Les principaux programmes de la Société comprennent ABO-102 (AAV-SGSH), une thérapie génique à base de virus adéno-associés (AAV) pour le syndrome de Sanfilippo de type A (MPS IIIA) et EB-101 (greffe de peau corrigée) pour l'épidermolyse bulleuse dystrophique récessive (RDEB). Elle développe également ABO-101 (AAV-NAGLU) pour le syndrome de Sanfilippo de type B (MPS IIIB), ABO-201 (AAV-CLN3) pour la thérapie génique de la maladie de Batten juvénile (JNCL), ABO-202 (AAV-CLN1) pour le traitement de la maladie infantile à Batten (INCL), EB-201 pour l'épidermolyse bulleuse, ABO-301 (AAV-FANCC) pour l'anémie de Fanconi et ABO-302 en utilisant une nouvelle approche d'édition génique CRISPR/Cas9 pour la thérapie génique des maladies rares du sang. La Société dispose également d'un portefeuille de produits protéinothérapeutiques à base de plasma, y compris un inhibiteur de protéase alpha-1 (SDF Alpha) pour la MPOC héréditaire, qui utilise son procédé exclusif sans éthanol de filtration au sel.
Nombre d'employés
: 42 personnes.
In the thread Trading Abeona Therapeutics Inc.
Buy beendet
Stopped prediction by melinda for Abeona Therapeutics Inc.
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€3.80
24.10.22
24.10.22
€4.50
24.10.23
24.10.23
-3.11%
25.10.23
25.10.23
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€19.80
17.10.21
17.10.21
€25.00
17.10.22
17.10.22
-15.53%
26.11.21
26.11.21
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€49.50
22.03.20
22.03.20
€75.00
04.11.21
04.11.21
-60.00%
17.10.21
17.10.21
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€36.50
14.03.20
14.03.20
€62.50
22.03.20
22.03.20
23.29%
22.03.20
22.03.20
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€76.00
15.02.20
15.02.20
€200.00
14.03.20
14.03.20
-51.97%
14.03.20
14.03.20
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€158.98
28.02.19
28.02.19
€270.60
12.03.19
12.03.19
9.36%
12.03.19
12.03.19
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€157.17
01.01.19
01.01.19
€214.23
28.02.19
28.02.19
1.15%
28.02.19
28.02.19
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€376.59
22.05.18
22.05.18
€483.70
31.05.18
31.05.18
4.94%
31.05.18
31.05.18
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€273.98
14.02.18
14.02.18
€383.35
19.03.18
19.03.18
23.05%
19.03.18
19.03.18
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€284.13
13.02.18
13.02.18
€383.35
14.02.18
14.02.18
-9.92%
14.02.18
14.02.18
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€420.56
06.10.17
06.10.17
€451.00
10.10.17
10.10.17
7.28%
10.10.17
10.10.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€277.37
30.08.17
30.08.17
€563.75
18.09.17
18.09.17
34.96%
18.09.17
18.09.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€307.50
30.08.17
30.08.17
€625.00
18.09.17
18.09.17
34.96%
18.09.17
18.09.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€192.50
11.08.17
11.08.17
€250.00
24.08.17
24.08.17
23.05%
24.08.17
24.08.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€173.64
11.08.17
11.08.17
€225.50
24.08.17
24.08.17
23.05%
24.08.17
24.08.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€110.50
27.01.17
27.01.17
€225.50
07.04.17
07.04.17
3.57%
07.04.17
07.04.17
Could be worthwhile Investment >10% per year
Abeona Therapeutics Inc.
Start price
Target price
Perf. (%)
€55.25
13.07.16
13.07.16
€60.89
29.07.16
29.07.16
10.61%
29.07.16
29.07.16
Could be worthwhile Investment >10% per year